CDKN2A and cancer: First, we analyzed The Cancer Genome Atlas (TCGA) database2 and confirmed that EBV-associated GC showed a high incidence of ARID1A and PIK3CA mutations along with CDKN2A (p16) silencing, as described in previous studies (Figures 1A and 1B).4